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Abstract: OBJECTIVE: The rs641738C>T variant located near the membrane-bound O-acyltransferase
domain containing 7 (MBOAT7) locus is associated with fibrosis in liver diseases, including non-alcoholic
fatty liver disease (NAFLD), alcohol-related liver disease, hepatitis B and C. We aim to understand
the mechanism by which the rs641738C>T variant contributes to pathogenesis of NAFLD. DESIGN:
Mice with hepatocyte-specific deletion of MBOAT7 (Mboat7hep) were generated and livers were char-
acterised by histology, flow cytometry, qPCR, RNA sequencing and lipidomics. We analysed the as-
sociation of rs641738C>T genotype with liver inflammation and fibrosis in 846 NAFLD patients and
obtained genotype-specific liver lipidomes from 280 human biopsies. RESULTS: Allelic imbalance anal-
ysis of heterozygous human liver samples pointed to lower expression of the MBOAT7 transcript on the
rs641738C>T haplotype. Mboat7hep mice showed spontaneous steatosis characterised by increased hep-
atic cholesterol ester content after 10 weeks. After 6 weeks on a high fat, methionine-low, choline-deficient
diet, mice developed increased hepatic fibrosis as measured by picrosirius staining (p<0.05), hydroxypro-
line content (p<0.05) and transcriptomics, while the inflammatory cell populations and inflammatory
mediators were minimally affected. In a human biopsied NAFLD cohort, MBOAT7 rs641738C>T was as-
sociated with fibrosis (p=0.004) independent of the presence of histological inflammation. Liver lipidomes
of Mboat7hep mice and human rs641738TT carriers with fibrosis showed increased total lysophosphatidyli-
nositol levels. The altered lysophosphatidylinositol and phosphatidylinositol subspecies in MBOAT7hep
livers and human rs641738TT carriers were similar. CONCLUSION: Mboat7 deficiency in mice and
human points to an inflammation-independent pathway of liver fibrosis that may be mediated by lipid
signalling and a potentially targetable treatment option in NAFLD.
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AbsTrACT
Objective The rs641738c>T variant located near the 
membrane- bound O- acyltransferase domain containing 7 
(MBOaT7) locus is associated with fibrosis in liver diseases, 
including non- alcoholic fatty liver disease (naFlD), 
alcohol- related liver disease, hepatitis B and c. We aim to 
understand the mechanism by which the rs641738c>T 
variant contributes to pathogenesis of naFlD.
Design Mice with hepatocyte- specific deletion of 
MBOaT7 (Mboat7Δhep) were generated and livers were 
characterised by histology, flow cytometry, qPcR, Rna 
sequencing and lipidomics. We analysed the association 
of rs641738c>T genotype with liver inflammation and 
fibrosis in 846 naFlD patients and obtained genotype- 
specific liver lipidomes from 280 human biopsies.
results allelic imbalance analysis of heterozygous 
human liver samples pointed to lower expression of the 
MBOaT7 transcript on the rs641738c>T haplotype. 
Mboat7Δhep mice showed spontaneous steatosis 
characterised by increased hepatic cholesterol ester 
content after 10 weeks. after 6 weeks on a high fat, 
methionine- low, choline- deficient diet, mice developed 
increased hepatic fibrosis as measured by picrosirius 
staining (p<0.05), hydroxyproline content (p<0.05) and 
transcriptomics, while the inflammatory cell populations 
and inflammatory mediators were minimally affected. in 
a human biopsied naFlD cohort, MBOaT7 rs641738c>T 
was associated with fibrosis (p=0.004) independent of 
the presence of histological inflammation. liver lipidomes 
of Mboat7Δhep mice and human rs641738TT carriers with 
fibrosis showed increased total lysophosphatidylinositol 
levels. The altered lysophosphatidylinositol and 
phosphatidylinositol subspecies in MBOaT7Δhep livers 
and human rs641738TT carriers were similar.
Conclusion Mboat7 deficiency in mice and human 
points to an inflammation- independent pathway of liver 
fibrosis that may be mediated by lipid signalling and a 
potentially targetable treatment option in naFlD.
InTrODuCTIOn
Non- alcoholic fatty liver disease (NAFLD) affects 
up to 30% of adults and 70%–80% of obese and 
diabetic individuals worldwide.1 NAFLD encom-
passes a spectrum of liver pathologies from simple 
steatosis (non- alcoholic fatty liver, NAFL) to non- 
alcoholic steatohepatitis (NASH) and eventually 
liver cirrhosis.2 3 Histopathological characteristics 
of NASH include steatosis, ballooning, inflam-
mation and fibrosis.3 4 A recent study indicated 
that severe fibrosis may be present in the absence 
of inflammation.5 NASH can further progress to 
cirrhosis, end- stage liver disease and hepatocellular 
carcinoma.1
Human genetic association studies have iden-
tified variation in several genes to be associated 
with NAFLD pathology, such as patatin- like phos-
pholipase domain- containing 3, transmembrane 
6 superfamily member 2 and also more recently 
membrane- bound O- acyltransferase domain 
containing 7 (MBOAT7).4 6 7 MBOAT7, a multis-
panning transmembrane protein, participates in acyl 
chain remodelling of phosphatidylinositol (PI) in the 
Lands cycle, by adding arachidonoyl- CoA (20:4) to 
1- stearoyl (18:0) lysophosphatidylinositol (LPI) 
thereby generating sn-1- stearoyl- sn-2- arachidonoyl 
significance of this study
What is already known on this subject?
 ► Non- alcoholic fatty liver disease (NAFLD) 
results from a multifactorial pathogenesis 
including genetic risk factors, obesity, intestinal 
dysbiosis and insulin resistance.
 ► Membrane- bound O- acyltransferase domain 
containing 7 (MBOAT7) has been previously 
reported as a risk gene in patients with liver 
diseases such as alcoholic and NAFLD, hepatitis 
B and C. Furthermore, reduced MBOAT7 protein 
in liver has been associated with altered 
phosphatidylinositol (PI) remodelling.
 ► MBOAT7 deficiency in mice reshapes the 
hepatic levels of PI and lysophosphatidylinositol 
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Table 1 Overview of the patients in the lipidomic cohort
normal control Healthy obese nAFL Early nAsH nAsH
Age 70.5 (63.5–74) 43.5 (35.3–48.0) 43 (34–52.5) 44 (34–51) 46.5 (35–51.2)
BMI 24.6 (21.7–26.3) 48.9 (44.3–52.5) 47.8 (42.2–52.7) 50.4 (44.2–54.1) 55.2 (49.6–59.2)
Sex % male 50 6.5 34.6 37.7 21.8
Fat (area in %) ≤5 ≤5 >5 >5 >5
NAS score 0 (0–0) 0 (0–0) 1 (1–2) 3 (2–3) 5 (5–6)
NAS fat 0 (0–0) 0 (0–0) 1 (1–2) 2 (1–2) 3 (3–3)
NAS ballooning 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1 (1–1)
NAS inflammation 0 (0–0) 0 (0–0) 0 (0–0) 1 (1–1) 1 (1–1.25)
Fibrosis 0 (0–0) 0 (0–0) 0 (0–1) 1 (0–1) 1 (1–1)
NAFLD without fibrosis
(CC/CT/TT)
NA NA 30/49/13 9/10/6 1/4/2
NAFLD with fibrosis (CC/CT/TT) NA NA 11/22/10 13/7/4 7/13/3
Total MBOAT7 rs641738 (CC/CT/TT) (n=280) 10/14/6 13/17/6 41/71/23 22/17/10 8/17/5
Patients are grouped by histology using the NAS score as the main classification criteria. Values are given as median with IQR in parentheses. Additional information is provided 
in online supplementary tables 8 and 9.
BMI, body mass index; MBOAT7, membrane- bound O- acyltransferase domain containing 7; NA, not applicable; NAFLD, non- alcoholic fatty liver disease; NAS, NAFLD Activity 
Score; NASH, non- alcoholic steatohepatitis.
significance of this study
What are the new findings?
 ► We report a hepatocyte specific deletion of MBOAT7 in mice 
using cre- loxP method and understanding its role in NAFLD.
 ► Disturbance of the PI side chain remodelling pathway in 
hepatocytes alone is sufficient to elicit spontaneous steatosis 
under steady state and fibrosis upon an induction diet—that 
is, hepatocytes themselves may serve as pathogenetic driver 
of fibrosis.
 ► Mboat7 deficiency in mice and humans defines a pathway to 
liver fibrosis that was independent of inflammation.
 ► Commonly implicated lipid mediators such as free fatty acids 
and oxylipins remain unchanged.
 ► Mboat7Δhep mouse model closely resembles the lipidomic 
changes in humans with the MBOAT7 risk variant.
 ► The fibrotic phenotype might be driven by extracellular lipid 
mediators—namely LPI.
How might it impact on clinical practice in the foreseeable 
future?
 ► Targeting PI signalling may be a novel approach to the 
treatment of NAFLD and liver fibrosis.
 ► Patients carrying the MBOAT7 mutation may be prone 
to fibrosis development without significant hepatic 
inflammation.
PI species.8–11 The identified human risk variant, MBOAT7 
rs641738T, has been associated with alcohol- related cirrhosis, 
NAFLD and with inflammation and fibrosis in chronic hepatitis 
B and C.12–18
In carriers of the rs641738C>T variant, reduced levels of 
MBOAT7 protein in the liver14 and hepatic- PI remodelling18 have 
been observed. Additionally, Mboat7 deficiency in mice reshapes 
the hepatic levels of PI and LPI and promotes hyperinsulinemia 
and hepatic insulin resistance.19 20 However, the mechanisms by 
which the rs641738C>T variant leads to NAFLD development 
and especially hepatic fibrosis are not sufficiently understood. 
Human genetic data on MBOAT7 point to a strong association 
of fibrosis across a range of different liver diseases.13 14 16–18 
Since fibrosis is the key prognostic marker for NAFLD21 and the 
endpoint of many current clinical studies on NASH,22 23 inves-
tigation of Mboat7- related disease pathways holds promise to 
provide additional insight into fibrosis progression of chronic 
liver disease.
Here, we present a combined analysis of a mouse model with 
hepatocyte- specific Mboat7 deletion with genetic and lipidomic 
analysis of human liver biopsies across the spectrum of NAFLD. 
We demonstrate that hepatocyte- specific deletion of Mboat7 in 
mice is sufficient to cause hepatic- steatosis at steady- state. On 
nutritional triggering with an NASH- inducing diet, MBOAT7 
deficiency resulted in a lipid- driven and inflammation- 
independent pathway towards liver fibrosis.
MATErIALs AnD METHODs
Human nAFLD cohort
A total of 846 adult Caucasian NAFLD patients from tertiary 
referral centres in Austria (n=258), Germany (n=537) and Swit-
zerland (n=51) who underwent percutaneous or surgical liver 
biopsy were included into this study (online supplementary tables 
1–2). NASH was defined by the NAFLD Activity Score. Presence 
of fibrosis was assessed histologically according to Kleiner clas-
sification24 (stage- F0:no fibrosis; stage- F1:perisinusoidal fibrosis 
to portal/periportal fibrosis; stage- F2:perisinusoidal and portal/
periportal fibrosis; stage- F3:bridging fibrosis). The liver biop-
sies were read by experienced pathologists in a blinded fashion. 
Portions of this NAFLD cohort have been described previ-
ously.25–27 All patients gave their written consent.
Human lipidomic cohort
A total of 280 human liver samples were obtained from patients 
in Germany, in whom an intraoperative liver biopsy was indi-
cated on clinical grounds such as during scheduled liver resection, 
exclusion of liver malignancy during major oncologic surgery or 
assessment of liver histology during bariatric surgery. Samples 
were snap frozen immediately in liquid nitrogen ensuring an ex 
vivo time of less than 40 seconds. Patients with evidence of viral 
hepatitis, haemochromatosis or alcohol consumption >20 g/day 
(women) and >30 g/day (men) were excluded. For all samples, 
MBOAT7 rs641738C>T genotype as well as full phenotypic 
and histological information24 generated by a single pathologist 
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Phenotypic groups (table 1) were defined on the basis of clinical 
and histological parameters.28
Mouse model
C57BL/6 mice with hepatocyte- specific deletion of Mboat7 
(Mboat7Δhep) were derived from crossing mice with a floxed 
Mboat7 allele with mice expressing Cre recombinase under 
the control of Albumin promoter (Albumin- Cre). Mboat7 
floxed mice, MBOAT7tm1c(KOMP)Wtsi, were purchased from MRC 
Harwell, Oxford, UK. Cre negative littermate mice with Mboat7 
floxed alleles (Mboat7WT) were used as controls. Mice were 
fed normal diet (Chow diet V1534-300, Ssniff Spezialdiäten) 
or a high- fat, methionine- low, choline- deficient diet (HFCDD, 
60% kcal fat, 0.1% methionine and choline- deficient diet; 
A06071302, research diets composition in online supplementary 
table 3) ad libitum. All experiments were performed according 
to the German animal welfare law and approved by the Landes-
direktion Sachsen, Germany.
Lipidomic analysis
Liver tissue (~25 mg) was homogenised and protein concen-
tration was determined by BCA/Pierce 660 assay. Lipids were 
extracted from aliquots containing 50 µg of total protein and 
quantified by shotgun lipidomics, as previously described.29 30 
Lipidomix, Berlin, performed oxylipin and free fatty acid (FFA) 
measurement in liver (~30 mg) using liquid chromatography 
electrospray ionisation tandem mass spectrometry (LC/ESI- MS/
MS).31
statistical analysis
Statistical analyses were performed using GraphPad software. 
For comparison of quantitative measurements, the Mann- 
Whitney U test or unpaired t test was used. Data are expressed 
as mean±SE of the mean.
See online supplementary section for detailed explanation on 
methods. Mouse data are additionally represented in the form of 
dot plots (online supplementary figures 13–19)
rEsuLTs
Analysis of allelic imbalance
Association of MBOAT7 rs641738C>T variant with lower 
mRNA expression and lower protein levels of MBOAT7 in human 
liver has been reported.14 As the downregulation of MBOAT7 
might be either caused by direct effects of the genomic variation 
or secondary effects, we analysed the relative allelic expression 
of rs8736 (LD to rs641738T: r2=0.98) in rs641738T hetero-
zygous individuals. Transcripts bearing rs8736 in the 3’UTR 
of MBOAT7 show a significantly (p<0.0001) lower expression 
than transcripts bearing the ancestral allele (figure 1A), thereby 
indicating a cis down- regulatory effect on the haplotype carrying 
the rs641738T allele.
Hepatocyte deletion of MbOAT7 in mice results in 
spontaneous steatosis characterised by increased cholesterol 
ester content
Previous data13 14 and our allelic imbalance analysis in human 
biopsies suggest, that reduced levels of MBOAT7 protein are 
the main locus- specific mechanism of contribution to NAFLD 
pathogenesis in rs641738C>T carriers. We, therefore, gener-
ated mice with hepatocyte- specific deletion of Mboat7 using 
loxP- flanked (‘floxed’) alleles of Mboat7 exon 5 (online 
supplementary figure 1A) and Cre- mediated deletion (Alb-Cre; 
Mboat7fl/fl mice; hereafter referred to as Mboat7Δhep mice). 
Littermate Cre negative Mboat7fl/fl mice were used as controls 
(Mboat7WT). Efficient deletion of Mboat7 in liver was veri-
fied at mRNA level (figure 1B and online supplementary figure 
1B) and Cre- loxP- mediated recombination was confirmed in 
primary hepatocytes by genomic- PCR (online supplementary 
figure 1C). We analysed liver histology in 10- week- old mice 
which were fed a normal diet. While there was no difference 
in liver weight (online supplementary figure 2A), livers from 
Mboat7Δhep animals contained more lipids than Mboat7WT 
mice as shown by H&E and Oil red O staining (figure 1C,D). 
Mboat7Δhep primary hepatocytes showed increased lipid accu-
mulation as compared with Mboat7WT cells, as shown by 
Oil red O staining (online supplementary figure 2B). Quan-
titative lipidomic analysis revealed the presence of steatosis 
in the Mboat7Δhep livers and primary hepatocytes was asso-
ciated with the accumulation of cholesteryl esters (CEs) but 
not triglycerides (TAGs) (figure 1E, online supplementary 
figure 2C). Specifically, CE 16:1, CE 16:0, CE 18:2 and CE 
18:1 were significantly increased in Mboat7Δhep livers (online 
supplementary figure 2D). Flow cytometry analysis revealed 
no differences in the number of non- parenchymal cells 
(NPCs), monocytes, macrophages and neutrophils between 
Mboat7Δhep and Mboat7WT livers (figure 1F–I, online supple-
mentary figure 2E–G). Quantitative real time PCR (qRT- PCR) 
analysis showed that mRNA expression of interferon-γ (IFN- 
gamma), tumour necrosis factor α (TNF- alpha), interleukin-1 
(IL1)- beta and IL6 were unaltered between the two groups 
(online supplementary figure 2H). Protein levels of inflamma-
tory mediators in the liver were unaltered between two groups 
(online supplementary figure 2I).
RNA sequencing of livers from Mboat7WT and Mboat7Δhep mice 
fed a normal diet was performed. Eighty- eight genes were signifi-
cantly downregulated and 98 genes were significantly upregulated 
following Mboat7 deletion (online supplementary table 4). Gene 
set enrichment analysis (GSEA) revealed a negative correlation 
between genes involved in fatty acid metabolism and hepatocyte 
specific Mboat7 deficiency (online supplementary figure 3A). Fatty 
acid oxidation- related genes such as Acaa1a, Acox1, Cpt1a, and 
Ehhadh were diminished and a lipogenic gene, Scd1 was upregu-
lated in Mboat7Δhep livers (online supplementary figure 3B). Signifi-
cantly altered genes from RNA sequencing, involved in fatty acid 
metabolism and cholesterol (Chol) metabolism were confirmed 
by qRT- PCR (online supplementary figure 3C). Furthermore, 
Angptl3, which is involved in lipoprotein metabolism was upreg-
ulated in Mboat7Δhep livers (online supplementary figure 3B and 
D); however, the circulating levels of Angptl3 protein was unal-
tered between the two groups (online supplementary figure 3E). 
GSEA revealed a positive correlation between genes involved in 
production of extracellular matrix (ECM) and Mboat7 deficiency 
(figure 1J).
Mboat7 deficiency promotes hepatic fibrosis on a high fat, 
methionine-low, choline-deficient diet in an inflammation 
independent manner
Mice were fed a HFCDD for 6 weeks to induce NAFLD. Both 
Mboat7Δhep and Mboat7WT mice accumulated lipids and showed 
no difference in liver weight (figure 2A,B). Although there was 
no visible difference in hepatic- lipid accumulation (figure 2B), 
Mboat7Δhep livers accumulated more CE with no changes in TAG 
levels (figure 2C). CE 16:1, CE 16:0, CE 18:3, CE 18:2, CE 
18:1, CE 18:0, CE 20:5 and CE 20:3 species were elevated in 
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Figure 1 Allelic imbalance and spontaneous steatosis phenotype of Mboat7Δhep in 10 weeks old mice fed with normal diet. (A) Relative allelic 
hepatic mRNA expression of MBOAT7 transcripts in rs641738C>T heterozygous individuals using the cSNP rs8736 that is in LD to rs641738T. Shown 
is the ratio of mutation carrying transcripts compared with transcripts bearing the ancient allele (left column). DNA (right column) was used as a 
control. n=37. (B–J) Data derived from Mboat7WT and Mboat7Δhep mice which were fed a normal diet. Data are presented as mean±SEM. **P<0.01 
(Mann- Whitney U test). (B) mRNA expression of Mboat7 was determined by qRT- PCR in Mboat7WT (n=6) and Mboat7Δhep (n=7) mice. (C) H&E 
staining of livers from 10- week- old Mboat7WT and Mboat7Δhep mice. (D) Oil red O staining of livers from 10- week- old Mboat7WT and Mboat7Δhep 
mice. Scale bars, 100 µm. (E) Hepatic- concentrations of triglyceride (TAG) and cholesterol ester (CE) (n=5 mice). (F–I) Flow cytometry analysis was 
performed in non- parenchymal cells (NPCs). (F) Total number of NPCs (n=6–7 mice). (G–I) Hepatic number of monocytes (CD45+/Ly6G-/CD11b+/F4/80-
), macrophages (CD45+/Ly6G-/CD11b+/F4/80+) and neutrophils (CD45+/Ly6G+/CD11b+) in livers of Mboat7WT and Mboat7Δhep mice (n=6–7 mice). (J) 
liver RNA sequencing in Mboat7WT and Mboat7Δhep mice. GSEA shows a positive correlation between ECM related genes and Mboat7 deficiency. qRT- 
PCR, quantitative real time- polymerase chain reaction; CE, cholesteryl ester; ECM, extracellular matrix; GSEA, gene set enrichment analysis; LD,linkage 
disequilibrium; MBOAT7, membrane- bound O- acyltransferase domain containing 7; NS, not significant; SEM, SE of the mean.
In the Mboat7Δhep mice we observed increased aspartate transam-
inase (AST) activity (online supplementary figure 4B) and alanine 
aminotransferase (ALT) activity showed a non- significant trend 
towards increase in Mboat7Δhep mice (online supplementary figure 
4C). Increased fibrosis was assessed by picrosirius red staining and 
western blot for TIMP1 in Mboat7Δhep mice (figure 2D,E and online 
supplementary figure 4D). The hepatic- hydroxyproline concen-
trations were increased by ~45% in the Mboat7Δhep as compared 
with Mboat7WT livers (p=0.031, figure 2F). On liver mRNA 
sequencing, 466 genes were upregulated and 112 genes were 
downregulated in Mboat7Δhep livers following HFCDD feeding 
(online supplementary table 5). In accordance with the picro-
sirius red and hydroxyproline measurements, pathways related 
to ECM, extracellular structure organisation, wound healing and 
tissue remodelling were significantly upregulated in Mboat7Δhep 
livers (figure 2G and online supplementary figure 5A). GSEA 
analysis showed a positive correlation between genes involved in 
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Figure 2 Mboat7- deficiency promotes hepatic fibrosis in mice on a high fat, methionine- low, choline- deficient diet in an inflammation independent 
manner. (A, C, D, F, J–L) data derived from Mboat7WT and Mboat7Δhep which were fed a HFCDD for 6 weeks. Data are presented as mean±SEM. 
*P<0.05, **P<0.01. (Mann- Whitney U test). (A) liver weight of Mboat7WT and Mboat7Δhep mice (n=7–8 mice). (B) H&E staining. Scale bars, 200 µm. 
(C) Hepatic- concentrations of TAG and CE (n=7–8 mice). (D, E) quantification (D) and representative images (E) of picrosirius red positive area in livers 
of Mboat7WT and Mboat7Δhep mice. Scale bars, 100 µm. (n=7–8 mice). (F) quantification of hydroxyproline (n=4–5 mice). (G–I) RNA sequencing results 
in livers of Mboat7WT and Mboat7Δhep mice. (G) heat map of significantly upregulated genes (FDR <0.05) in Mboat7Δhep livers from the extracellular 
matrix organisation pathway (from online supplementary figure 5A). (H) GSEA shows a positive correlation between the extracellular matrix related 
genes and Mboat7 deficiency. (I) heat map of collagen subtypes that were significantly (FDR <0.05) upregulated in the Mboat7Δhep livers. (J) qRT- 
PCR results (n=4–5 mice). (K, L) flow cytometry analysis of NPCs, (total NPCs, monocytes, macrophages, neutrophils, CD4, CD8 T cells) isolated from 
livers of Mboat7WT and Mboat7Δhep mice. (n=4–5 mice). CE, cholesteryl ester; GSEA, gene set enrichment analysis; HFCDD, high- fat, methionine- low, 
choline- deficient diet; MBOAT7, membrane- bound O- acyltransferase domain containing 7; FDR, False discovery rate; NPCs, non- parenchymal cells; 
SEM, SE of the mean; TAG, triglyceride.
of collagen subtypes such as Col6a3, Col4a5, Col4a4, Col6a1, 
Col6a2, Col1a2, Col1a1, Col3a1, Col5a2, Col15a1, Col8a1 
and Acta2 were elevated in the Mboat7Δhep livers (figure 2I and 
online supplementary figure 5B). Several ECM- related genes were 
further confirmed by qRT- PCR with consistent results (figure 2J). 
Various lipid metabolic pathways and ‘inflammatory response’ 
pathways were downregulated in livers of Mboat7 deficient mice 
following HFCDD feeding (online supplementary figure 5C). 
Intriguingly, there were no differences in the number of NPCs, 
macrophages, neutrophils, CD4 T cells and CD8 T cells between 
the two groups on flow cytometry analysis (figure 2K,L). Nominal 
numbers of monocyte population were reduced in Mboat7Δhep 
livers (figure 2L). However, the percentage of inflammatory cells 
were unchanged (online supplementary figure 5D). Inflammatory 
mediators such as TNF- alpha, IL6, IL1- beta and IFN- gamma were 
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5E) and on mRNA sequencing (data not shown). Protein levels of 
TNF- alpha and KC/GRO were increased and IL2 was decreased 
in Mboat7Δhep livers, whereas IFNγ, IL1β, IL4, IL5, IL6, IL10 and 
IL12p70 were unaltered between the two groups (online supple-
mentary figure 5F). Markers of ER stress were not altered in the 
Mboat7Δhep liver (online supplementary figure 6A–K).
The MbOAT7 rs641738C>T variant is associated with hepatic 
fibrosis in humans with a body mass index ≤35 independent 
of the presence of inflammation
We analysed the frequency of the rs641738C>T allele in patients 
(separately in body mass index (BMI) ≤35 and BMI >35) from a 
cross- sectional NAFLD liver biopsy cohort stratified by the pres-
ence of liver fibrosis and lobular inflammation. In patients with 
BMI ≤35, the rs641738C>T allele was significantly associated 
with the presence of fibrosis (F1- F4) in the absence of lobular 
inflammation (p=0.001; OR=1.91 (1.27–2.87), figure 3A). In 
the presence of lobular inflammation (1–3), the association of 
the rs641738C>T allele with the presence of fibrosis yielded a 
similar odds ratio (p=0.289; OR=1.70 (0.64–4.56)), suggesting 
the development of fibrosis may be independent of inflammation 
in patients carrying the rs641738C>T variant (figure 3A). Inter-
estingly, in morbidly obese patients with a BMI >35, no associa-
tion of rs641738C>T genotype with the presence of histological 
fibrosis was observed (figure 3B).
Mboat7Δhep mice do not exhibit altered hepatic levels of FFA 
and oxylipins
As Mboat7 functions by adding arachidonoyl- CoA (20:4) to 
1- stearoyl (18:0) LPI (online supplementary figure 7),9 32 33 we 
hypothesised that Mboat7 deficiency could lead to altered levels of 
FFA and fatty acid metabolites (oxylipins) in the liver. Therefore, 
we measured the hepatic concentrations of FFA and oxylipins in 
Mboat7WT and Mboat7Δhep mice. We found no significant differ-
ences in the levels of FFA between the two groups both on a 
normal diet and on HFCDD feeding (figure 3C,D). On correction 
for multiple testing across both diets, there was no difference in 
the hepatic oxylipin concentrations between the Mboat7WT and 
Mboat7Δhep mice on normal diet (online supplementary table 6) 
and after HFCDD (online supplementary table 7).
Lipidomic analysis of PI and LPI species in mouse liver
Given the biochemical function of Mboat79 32 33 (online supple-
mentary figure 7), hepatocyte- specific knockout of the enzyme 
might have an impact on the molecular composition and molar 
abundance of LPI and PI. In normal diet fed mice, total LPI 
levels were increased from 0.59±0.11 pmol/µg of total protein 
in Mboat7WT livers to 2.72±0.26 pmol/µg in Mboat7Δhep livers 
(figure 4A). LPI 20:4 was diminished in Mboat7Δhep livers while 
LPI 16:0, LPI 18:1 and LPI 18:0 were increased (figure 4A,B). Of 
note, LPI 18:1 was not detected in Mboat7WT but was induced 
in Mboat7Δhep livers (figure 4B). Total PI levels were reduced in 
Mboat7Δhep livers (figure 4A). As reported previously, PI 38:4 was 
the most abundant PI species accounting for 88% of total PI in 
Mboat7WT livers (data not shown).19 PI38:4 was strikingly down-
regulated with ~60% reduction in Mboat7Δhep livers as compared 
with Mboat7WT livers (figure 4C). In addition to PI38:4, PI36:4 
and PI38:5 were also significantly reduced in the Mboat7Δhep livers 
(figure 4C). In addition to PI and LPI, phosphatidylglycerol (PG), 
lysophosphatidylglycerol (LPG) and phosphatidic acid (PA) were 
elevated in the livers of Mboat7 deficient as compared with Mboat7 
sufficient mice (figure 4A). The hepatic levels of other phospho-
lipid classes such as PC, PE, PS, PC- O and lysophospholipids such 
as lysophosphatidylethanolamine (LPE) and lysophosphatidylcho-
line (LPC), ceramides, sphingomyelin (SM), diacylglycerol and 
Chol were unaltered (figure 4A). In order to identify alterations 
in the hepatocyte lipidome, we performed lipidomic analysis in 
isolated primary hepatocytes from Mboat7WT and Mboat7Δhep 
mice (online supplementary figure 8A). Similar to total liver, we 
found that LPI and PG levels were enhanced in Mboat7Δhep hepato-
cytes as compared with Mboat7WT hepatocytes (online supple-
mentary figure 8A), demonstrating that the significant alterations 
observed in the liver lipidome (figure 4A) mainly originated from 
the hepatocytes.
In mice fed the HFCDD demonstrating the fibrotic liver 
phenotype, key phospholipids were also altered (figure 4D–F): 
Total LPI levels and LPI species LPI 16:0, LPI 18:1 and LPI 18:0 
were increased in Mboat7Δhep livers (figure 4D–E). LPI 18:1 was 
not detected in Mboat7WT livers but was upregulated following 
hepatocyte- specific Mboat7 deletion (figure 4E). Other phospho-
lipids and lysophospholipids such as PG, LPG, PC, PE, PS, PE O-, 
PC O-, LPE, LPC and SM were also increased in Mboat7Δhep livers 
during NAFLD (figure 4D). PI 38:4 was significantly reduced, 
whereas PI 34:2, PI 36:3, PI 36:2, PI 38:6, PI 40:7, PI 40:6 and 
PI 40:5 were increased in Mboat7Δhep livers as compared with 
Mboat7WT livers (figure 4F).
Lipidomic analysis of human liver biopsies
We performed a lipidomic analysis in a cross- sectional liver biopsy 
cohort (table 1) stratified by the rs641738C>T genotype. Except 
for cardiolipin, we found no differences in total amounts of lipid 
classes between CC, CT and TT groups (figure 5A–C). In individ-
uals carrying the rs641738TT risk genotype, profound remodel-
ling of PI species was observed, specifically PI 32:0, PI 32:1, PI 
34:1, PI 34:2, PI 36:1, PI 36:2, PI 38:6, PI 40:5 and PI 40:6 were 
elevated in the TT group compared with the CC group, whereas 
PI 40:4, PI 36:4 and PI 38:4 were reduced in the TT group 
(figure 5D,E). The decrease of PI 38:4 in rs641738TT samples was 
also observed when stratified for disease condition, specifically in 
NAFL, early NASH and NASH samples (online supplementary 
figure 9A). Furthermore, LPI 18:0 levels were increased (p=0.002) 
and LPI 20:4 levels were decreased (p=0.009) in the TT group as 
compared with the CC group (figure 5F). By stratifying for pres-
ence or absence of fibrosis, we found that total LPI levels were posi-
tively correlated with rs641738TT genotype only in the presence 
of fibrosis (figure 5G). Additionally, LPA levels were also correlated 
with the rs641738TT genotype only in the presence of fibrosis, 
whereas other lipid classes were unaltered (online supplementary 
figure 9B–D). In the absence of fibrosis, no alterations were found 
in the CC as compared with the TT groups (online supplemen-
tary figure 9E–G). Changes in molecular composition of PI and 
LPI species were remarkably similar between humans homozygous 
for the MBOAT7 rs641738TT risk variant and Mboat7 deficient 
mice under normal diet and after HFCDD feeding (figure 5H–M). 
On stratifying for both, the MBOAT7 rs641738C>T genotype 
and disease condition, we observed significant first broad changes 
between phenotypic groups in lipid class compositions (online 
supplementary figure 10A–O). Alterations in lipid classes in the 
MBOAT7 genotype- specific analysis were observed in the normal 
control, NAFL, early NASH and NASH groups, whereas no differ-
ences were found in the healthy obese group. Consistent with the 
highest proportion of samples with histological fibrosis, genotype- 
specific lipid class alterations were most pronounced in the 
NASH group (online supplementary figure 10M–O). Lipidomic 
comparison of fibrotic and non- fibrotic NAFL revealed significant 
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Figure 3 The MBOAT7 rs641738T variant associates with fibrosis independent of inflammation. Hepatic Mboat7 deficiency is not associated with 
altered free fatty acids in mice. (A, B) the frequency of the MBOAT7 rs641738C>T allele in NAFLD patients (A) BMI ≤35 (without inflammation, F0, 
n=215; without inflammation, F1–4, n=74; with inflammation, F0, n=10; with inflammation, F1–4, n=62) and (B) BMI >35 (without inflammation, F0, 
n=231; without inflammation, F1–4, n=96; with inflammation, F0, n=64; with inflammation, F1–4, n=94) from a cross- sectional liver biopsy cohort, 
stratified by the presence of liver fibrosis and lobular inflammation. Genetic analyses were calculated using an additive model. Differences between 
the groups were compared by logistic regression analysis adjusted for sex, age, BMI and presence of T2DM (online supplementary table 1 & 2). (C, D) 
hepatic free- fatty acid levels on normal diet (C) and HFCDD diet (D). Data are presented as mean±SEM. (n=6–8 mice). BMI, body mass index; HFCDD, 
high- fat, methionine- low, choline- deficient diet; MBOAT7, membrane- bound O- acyltransferase domain containing 7; NAFLD, non- alcoholic fatty liver 
disease; T2DM, Type 2 Diabetes mellitus; MAF, Minor allele frequency; SEM, SE of the mean.
supplementary figure 9B–G). Results were robust to exclusion of 
patients on statin medication (n=14) as shown in online supple-
mentary figure 11A–C.
DIsCussIOn
NAFLD encompasses a broad phenotypic spectrum from benign 
steatosis to liver cirrhosis and liver- related death.2 3 The strongest 
and ultimately sole prognostic factor for liver- related mortality 
is the presence and progression of fibrosis. Interestingly, fibrosis 
can occur in up to 30% of patients without relevant inflam-
mation.5 In contrast to its clinical and prognostic relevance, 
the process of fibrogenesis in the context of NAFLD is poorly 
understood. Discovery of the MBOAT7 locus, which is associ-
ated with a strong fibrotic signature in human NAFLD, alcoholic 
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Figure 4 Lipidomic analysis of mouse liver on normal and HFCDD 
diet. (A–F) data are presented as mean±SEM. (Mann- Whitney U test). 
*P<0.05, **P<0.01, ***P<0.001. lipidomic analysis of livers on a 
normal diet (A–C, n=5 mice) and HFCDD diet (D–F, n=7–8 mice). Cer, 
ceramides; Chol, cholesterol; DAG, diacylglycerol; HFCDD, high- fat, 
methionine- low, choline- deficient diet; LPC, lysophosphatidylcholine; 
LPE, lysophosphatidylethanolamine; LPG, lysophosphatidylglycerol; 
LPI, lysophosphatidylinositol; MBOAT7, membrane- bound O- 
acyltransferase domain containing 7; ND, not detected; PA, phosphatidic 
acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, 
phosphatidylglycerol; PI, phosphatidylinositol; SEM, SE of the mean; SM, 
sphingomyelin.
for uncovering novel mechanisms underlying hepatic fibrogen-
esis of broad relevance. Here, we provide a combined mouse 
and human dataset that advances our knowledge pertinent to 
NAFLD- related fibrosis and at the same time challenges several 
central paradigms of current NAFLD research.
We demonstrate that a disrupted PI remodelling pathway 
in hepatocytes is associated with phenotypes on standard and 
a NASH- inducing diet: Mboat7Δhep mice developed sponta-
neous steatosis on normal diet. Steatosis was characterised by 
increased Chol esters while TAGs were unchanged. The lipo-
genic enzyme, Scd1 (SCD1, stearoyl- CoA desaturase) was 
upregulated and several fatty acid oxidation genes were down-
regulated in Mboat7 deficient livers at steady state. The major 
product of SCD1 is oleic acid (18:1) which is the preferred 
substrate for acyl- CoA:cholesterol acyltransferase, the Chol 
esterification enzyme.34 35 The reduced fatty- acid oxidation 
and increased SCD1 may at least partly explain the increased 
CE levels and spontaneous steatosis seen in Mboat7- deficient 
livers, however, further investigation is required to completely 
understand the mechanisms involved. Similar to the current 
study, it was shown recently that silencing Mboat7 in mice using 
antisense oligonucleotide conjugated with morpholinos results 
in spontaneous lipid accumulation in the liver; however, the 
study concludes that this was due to increased TAG accumula-
tion although CE levels were not measured in their samples.36 
Another study, in which antisense oligonucleotides were used to 
knock down Mboat7 in adipose tissue, liver and cells of the retic-
uloendothelial system reported no spontaneous phenotype.20 
However, following high- fat diet (HFD) feeding, these mice 
exhibited elevated levels of TAGs and CEs in the liver.20 The 
phenotypic differences seen between these previous studies and 
the current study might be explained by the broader knock- down 
of Mboat7 using the antisense oligonucleotide approach20 36
Disturbed lipid metabolism in hepatocytes is sufficient to 
drive liver fibrosis
After HFCDD feeding, Mboat7Δhep mice developed increased 
hepatic- fibrosis as measured by picrosirius staining and relative 
hepatic hydroxyproline content and transcriptomic analysis 
revealed a broad upregulation of ECM genes. Thus, disturbance 
of the PI side chain remodelling pathway in hepatocytes elicits 
fibrosis on an induction diet—that is, hepatocytes themselves 
may serve as a pathogenic driver of fibrosis.
Mboat7-deficiency elicits liver fibrosis in the absence of 
inflammation
We found that, the MBOAT7 risk variant was associated with 
hepatic fibrosis independent of the presence of inflammation. 
This represents an intriguing and novel mechanism for liver 
fibrosis, suggesting that hepatocyte signalling in the fibrogenic 
mesenchymal cell compartment, that is, primarily myofibroblasts/
hepatic stellate cells, is sufficient to induce fibrosis without an 
increased inflammatory infiltrate. Mancina et al have shown that 
MBOAT7 rs641738C>T is associated with more necroinflam-
mation.14 In mice, Helsley et al have shown that HFD feeding of 
Mboat7 deficient mice results in reduced hepatic- accumulation 
of total macrophages and M2 macrophages, whereas, CD8+T 
cells and M1 macrophages were increased.20 Differences in the 
inflammatory cell accumulation seen between the current study 
and the study by Helsley et al may be due to the strategy they 
used for Mboat7 deletion (antisense oligonucleotide) which is 
known to silence Mboat7 in adipose tissue, liver and cells of the 
reticuloendothelial system, which includes macrophages; there-
fore, these changes in inflammatory cells could derive from the 
loss of macrophage- specific Mboat7 function.20 Moreover, in 
the study by Helsley et al, mice were treated with the antisense 
oligonucleotide to silence Mboat7 concurrently during HFD 
feeding, therefore, Mboat7 was not silenced before the start of 
the feeding.
FFA and oxylipins are unchanged in the fibrotic mouse 
phenotype
Since Mboat7 exhibits LPI acyltransferase activity towards 
arachidonoyl- CoA,8 deletion of Mboat7 could lead to elevated 
levels of free arachidonic acid and the generation of its proin-
flammatory lipid metabolites. However, we found no significant 
increase in FFA and oxylipins in Mboat7Δhep mice, suggesting that 
these lipid mediators and arachidonic acid- derived metabolites 
do not contribute to fibrosis development in this model. These 
findings are concordant to a recent study that has shown that 
arachidonic acid- derived proinflammatory lipid mediators were 
not altered in the livers of Mboat7 deficient mice.20 37 Because 
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Figure 5 Lipidomic analysis of human liver biopsies stratified by MBOAT7 rs641738C>T genotype. (A–E) lipidomic analysis of human livers 
(lipidomic cohort) stratified by rs641738C>T genotype (not grouped for a disease condition, age, sex, and BMI). Data are presented as mean±SEM, 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Patient samples in which a specific lipid class was not detected were excluded from analysis. 
Alterations in PI and LPI species are presented as mol% (% of total PI and % of total LPI). (A) alterations in hepatic triglyceride (TAG) levels. CC, 
n=94; CT, n=136; TT, n=50. (B) alterations in hepatic lipid classes. CC, n=94; CT, n=136; TT, n=50. (C) alterations in hepatic lipid classes. CER, 
ceramide (CC, n=94; CT, n=136; TT, n=50); CL*, cardiolipin (CC, n=55; CT, n=87; TT, n=24); LPA*, lyso- phosphatidate (CC, n=45; CT, n=56; TT, 
n=11); LPC, lysophosphatidylcholine (CC, n=94; CT, n=136; TT, n=50); LPE, lysophosphatidylethanolamine (CC, n=94; CT, n=136; TT, n=50); LPG*, 
lysophosphatidylglycerol (CC, n=87; CT, n=123; TT, n=48); LPI*, lysophosphatidylinositol (CC, n=85; CT, n=120; TT, n=48); LPS*, lysophosphatidylserine 
(CC, n=91; CT, n=132; TT, n=48). *Patient samples in which a specific lipid class was not detected were excluded from analysis. (D) Alterations in PI 
species presented as mol% (% of total PI). CC, n=94; CT, n=136; TT, n=50. (E) Alterations in PI species presented as mol% (% of total PI). *PI 32:0 
(CC, n=68; CT, n=103; TT, n=37) *PI 32:1 (CC, n=54; CT, n=59; TT, n=30) *PI 34:0 (CC, n=87; CT, n=116; TT, n=37); *PI 34:1 (CC, n=92; CT, n=128; TT, 
n=46); *PI 34:2 (CC, n=93; CT, n=130; TT, n=46); *PI 36:1 (CC, n=93; CT, n=136; TT, n=50); *PI 38:3 (CC, n=3; CT, n=7; TT, n=3); *PI 38:6 (CC, n=92; 
CT, n=128; TT, n=50); *PI 40:4 (CC, n=34; CT, n=41; TT, n=11); *PI 40:7 (CC, n=27; CT, n=32; TT, n=19). *Patient samples in which a specific lipid 
species was not detected were excluded from analysis. (F) Alterations in LPI species presented as mol% (% of total LPI). CC, n=10; TT, n=7. (analysis 
was done on patient liver samples in which 4 LPI species were detected). (G) comparison of total LPI level in NAFLD (include NAFL, early NASH and 
NASH samples) patient livers with and without the presence of fibrosis. with fibrosis, CC, n=25; with fibrosis, TT, n=17; without fibrosis, CC, n=39; 
without fibrosis, TT, n=20. NS, not significant. (Patient samples in which no LPI species was detected were excluded). (H–M) Difference of means of 
common PI and LPI species (mol%) in mice and humans. (H, K) Lipidomic analysis of human livers obtained from people with either the CC or TT 
genotype (not grouped for a disease condition, age, sex, and BMI), (I, L) livers from Mboat7WT and Mboat7Δhep mice fed a normal diet and (J, M) livers 
from Mboat7WT and Mboat7Δhep mice fed an HFCDD for 6 weeks. (H, K) Difference of means (mol% values, TT- CC) of PI and LPI species in human 
livers. (I, L) Difference of means (mol% values) of PI and LPI species in Mboat7WT and Mboat7Δhep mice fed a normal diet (Mboat7Δhep - Mboat7WT). 
n=5 mice. (J, M) Difference of mean (mol% values) of PI and LPI species in Mboat7WT and Mboat7Δhep mice fed an HFCDD (Mboat7Δhep - Mboat7WT). 
n=7–8 mice. BMI, body mass index; DAG, diacylglycerol; NAFL, non- alcoholic fatty liver; MBOAT7, membrane- bound O- acyltransferase domain 
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mediators38–40 this finding is consistent with the lack of changes 
in the lobular inflammatory compartment.
resemblance of human nAFLD and the mouse model
Interestingly, the lipidomic changes associated with hepatocyte- 
specific Mboat7 deficiency closely resemble the lipidomic alter-
ations in humans with the MBOAT7 risk variant and may thus 
represent a promising model to gain further insights into the 
patients with NAFLD fibrosis, although all NALFD patients 
in this study were recruited from bariatric surgery. Further-
more, murine and human data are in agreement with regard 
to the genetic association of MBOAT7 genotype with fibrosis 
and inflammation: We show that the correlation between the 
rs641738C>T variant and hepatic- fibrosis was indeed indepen-
dent of inflammation in our biopsied NAFLD patients with a 
BMI≤35.
novel lipid signalling targets in nAFLD
Mboat7 functions in the Lands’ cycle, where it adds arachidonic 
acid (20:4) to 1- stearoyl (18:0) LPI thereby generating sn-1- 
stearoyl- sn-2- arachidonoyl PI species,9 which in turn might lead 
to increased LPI levels and an altered PI spectrum if Mboat7 is 
absent in liver. In the absence of Mboat7, alterations in PI species 
have been reported in mice, humans and in cultured hepato-
cytes, previously.14 18 19 36 We confirm and extend these find-
ings through broader and liver- specific lipidomics in mice and 
humans and observe characteristic genotype- specific alterations 
in lysolipid patterns between fibrotic and non- fibrotic NAFL 
(online supplementary figure 9B–G, figure 5G). Intriguingly, 
the lipidomic patterns in mouse Mboat7Δhep livers and humans 
carrying the rs641738TT variant showed striking similarities. 
We demonstrate a profound remodelling of PI with a reduction 
of PI species containing arachidonoyl side chains and increase of 
other PI species particularly with monounsaturated fatty acids. 
Increased LPI levels and particularly LPI 18:0 correlated with 
the presence of fibrosis in the human rs641738TT genotype and 
in the murine fibrotic phenotype. LPI is exported from cells via 
ABCC1,41–43 thereby rendering it a candidate profibrotic lipid 
mediator, which might directly interact with the stellate cell 
compartment. Circulating LPI levels are significantly increased 
in patients with liver fibrosis as compared with healthy people20 
and treating obese mice with exogenous LPI 18:1 promotes 
pro- fibrotic gene expression in the liver.20 LPI might thus play a 
signalling role in fibrosis development.
In summary, our combined murine and human data provide 
novel insights into NAFLD pathogenesis (online supplementary 
figure 12). Further mechanistic studies of the new candidate lipid 
mediators and their effects on other hepatic cell populations are 
required to provide a deeper understanding of these pathways 
and to transform them into viable target molecules.
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